Retractable Technologies Inc. has released its financial results for the third quarter of 2026, revealing a significant increase in sales but continuing to face substantial operating losses. The company reported total net sales of $14.1 million for the quarter, up from $10.1 million in the same period last year. Despite the rise in sales, the operating loss grew to $4.1 million, compared to a loss of $3.7 million in Q3 2025. This announcement is crucial as it highlights the company's ongoing struggle to achieve profitability in a competitive and evolving market.
Retractable Technologies, Inc. operates in the surgical and medical instruments and apparatus sector, specifically categorized under SIC 3841. The company is publicly traded under the ticker symbol RVP on the NYSE American exchange. Recent filings include a Form 10-Q filed on the same day as the 8-K, indicating ongoing regulatory compliance and financial reporting activities.
The filing details that the increase in net sales for the third quarter of 2026 was primarily driven by consistent purchasing patterns during the flu season, which aligned more closely with historical trends compared to the previous year. The company noted that in 2025, flu season sales were unusually high in the second quarter, affecting year-over-year comparability.
Additionally, the filing states, "We continue to lessen the financial impact of tariffs by producing certain products domestically and strategically ordering certain products from our Chinese suppliers." This indicates the company's proactive approach to managing costs and supply chain challenges. Domestic production accounted for 40.3% of units manufactured in the first nine months of 2026, reflecting a strategic shift to mitigate tariff impacts.
Despite the increase in sales, Retractable Technologies reported net losses of $(2.4) million for the third quarter and $(3.8) million for the first nine months of 2026. These figures include a $6.4 million gain from the sale of equity securities, which underscores the complexity of the company's financial landscape. The loss from operations for the nine-month period was $15.5 million, compared to $13.5 million in the same timeframe last year.
The results indicate a shift in product mix, with domestic unit sales increasing significantly, primarily due to the timing of EasyPoint® product orders. The company noted that domestic net sales accounted for 90.3% of total sales in Q3 2026, although the overall domestic net sales saw a slight decrease of 2.1% for the nine months ended September 30, 2026.
Looking ahead, the company continues to face challenges related to tariffs and market dynamics. Approximately $260,000 was spent on tariff expenses in Q3 2026, highlighting the ongoing financial pressures from international trade policies. The filing does not specify what actions the company will take next, but it emphasizes the need for ongoing strategic adjustments to navigate these challenges.
Read Next
KiNRG, Inc. Reports Quarterly Results for Q3 2026
Quarta-Rad Reports Q3 2026 Results, Highlights Industry Challenges
Goldenwell Biotech reports Q3 results, shows ongoing growth
Totaligent reports Q3 results, highlights industry challenges
Cal Redwood Acquisition Corp. reports Q3 results for 2026
Powerdyne International reports Q3 results amid industry shifts







